Zydus’ biopharma arm acquires global proprietary rights for Progeria treatment

Sentynl, under Zydus Lifesciences, acquired global rights for Zokinvy, the first FDA-approved Progeria treatment. An acquisition milestone in expanding the rare disease medicines portfolio, focusing on supporting patients.